IRWD.US Ironwood Pharmaceuticals Inc

Healthcare Biotechnology USA Stocks
4.83 USD
Close of Nov 15, 2026
2.95 5.78
Market cap
USD 800M
P/E
5.4x
P/B
2.59x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IRWD.US undervalued?

Graham number
Price4.83
Graham value6.15
Discount21.4%

IRWD.US trades 21.4% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ironwood Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Ironwood Pharmaceuticals Inc yet.

Ironwood Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZE…

Full company profile